Hosted by Bioethics International & EY, with Yale Medicines Access Network (YMAN), the Yale Program for Biomedical Ethics, and Scientific American
SAVE THE DATE
Monday, May 3, 2027
8:00 AM – 6:00 PM ET
New York City
ABOUT THE ROUNDTABLE
Now in its 18th year, this roundtable is the leading forum where senior leaders from pharmaceutical and biotech companies, academia, patient advocacy, and health policy come together for a full day of candid, high-level dialogue on bioethics and patient centricity in medicine development and access.
Each year, the conversation addresses three core questions: What does success look like? How do we measure progress? And who is already leading the way?
The day combines plenary talks from prominent voices in medicine and regulation with working sessions built around the latest findings from the Good Pharma Scorecard, offering participants a rare opportunity to shape the latest metrics that define industry leadership.
PARTICIPANTS AT LAST YEAR’S EVENT
The caliber of past roundtables reflect the seriousness of the conversation you can expect in 2027: Last year’s Roundtable featured:
- Robert Califf, MD (Former Commissioner, U.S. Food and Drug Administration)
- Patrice Matchaba, MD (CEO, Gates Medical Research Institute; Former Group Head, Novartis Global Health)
- Arthur Caplan, PhD (Founding Head, Division of Medical Ethics, NYU School of Medicine)
- Julie Gralow, MD, Chief Medical Officer, American Society of Clinical Oncology
- Jennifer Miller, PhD, (Founder, Bioethics International; Co-Director, Yale Program for Biomedical Ethics)
Roundtables regularly include C-suite and senior leaders from companies such as Novartis, Pfizer, Sanofi, Bristol Myers Squibb, Takeda, Roche, GSK, Regeneron, Sarepta Therapeutics, and CSL, alongside leaders from the FDA, WHO, Yale School of Medicine, and major patient advocacy organizations.
WHAT THE DAY COVERS
The 2027 agenda is in developed, but participants can expect the roundtable’s signature mix of plenary talks, panel discussions, and working sessions built around themes such as:
- Transparency and data sharing in clinical research
- How C-suite leaders navigate competing ethical priorities
- Designing clinical trials that represent the patients they serve
- Global access to novel medicines in the countries where trials are conducted
- Building shared goals and metrics for patient centricity across the industry
————————————————————————————————————————-
HOSTS AND PARTNERS
Bioethics International
A 501(c)(3) public charity founded in 2005 to advance ethics, trustworthiness, and patient centricity in healthcare.
EY
Global professional services organization helping build trust and confidence in economies and capital markets worldwide.
Yale Program for Biomedical Ethics
A cross-disciplinary Yale program advancing education, research, and clinical practice in medical ethics.
Yale Medicines Access Network
A Yale-based network focused on expanding equitable access to medicines worldwide.
Scientific American
The longest continuously published magazine in the U.S. and a leading authority on science and technology since 1845.
————————————————————————————————————————-
RESERVE MONDAY, MAY 3, 2027
Space at the Roundtable is limited and by invitation only to keep the discussion high level and candid.
See our 2026 Agenda
APPLY TO PARTICIPATE
If you wish to apply to join us in 2027, email sue@bioethicsinternational.org expressing your interest and we will share the preliminary agenda and registration details as soon as they’re available.